Dendreon Corporation Promotes Grant E. Pickering to Vice President of Operations to Oversee Expanding Product Development Pipeline.Business Editors & Health/Medical Writers BIOWIRE2K SEATTLE--(BW HealthWire)--March 15, 2002 Dendreon Corporation (Nasdaq:DNDN) announced today that Grant E. Pickering has been promoted to Vice President of Operations. In this newly-created position, Pickering will be responsible for clinical development, marketing and sales operations at the company, with a specific focus on clinical development of the company's expanding product pipeline. "Given the late-stage development of Dendreon's vaccine products and a burgeoning product pipeline that includes other therapeutic vaccines, promising antibody candidates and a pathway to small molecules, we need to expand and strengthen the infrastructure necessary to fully capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. these promising opportunities," said David L. Urdal, Ph.D., Dendreon's president and chief scientific officer. "Grant's unique combination of product development and marketing experience will solidify a market-driven approach to the development and commercialization of our products." Frank H. Valone, M.D., head of clinical affairs, will be leaving the company for personal reasons to spend more time with his family. About Dendreon Dendreon Corporation is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon's lead product, ProvengeTM, a therapeutic vaccine for the treatment of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , is currently in Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . Dendreon has two other therapeutic cancer vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. candidates in clinical trials -- MylovengeTM, for the treatment of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , in Phase II trials; and APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024, for the treatment of breast, ovarian and colon cancers, in Phase I trials. Dendreon's product pipeline also includes monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). and a pathway to small molecules. For more information, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the uncertainty of Dendreon's future access to capital, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
|||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion